Goudouris Ekaterini Simões, Rego Silva Almerinda Maria do, Ouricuri Aluce Loureiro, Grumach Anete Sevciovic, Condino-Neto Antonio, Costa-Carvalho Beatriz Tavares, Prando Carolina Cardoso, Kokron Cristina Maria, Vasconcelos Dewton de Moraes, Tavares Fabíola Scancetti, Silva Segundo Gesmar Rodrigues, Barreto Irma Cecília, Dorna Mayra de Barros, Barros Myrthes Anna, Forte Wilma Carvalho Neves
Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil.
Universidade Federal de Pernambuco, Recife, PE, Brazil.
Einstein (Sao Paulo). 2017;15(1):1-16. doi: 10.1590/S1679-45082017AE3844.
In the last few years, new primary immunodeficiencies and genetic defects have been described. Recently, immunoglobulin products with improved compositions and for subcutaneous use have become available in Brazil. In order to guide physicians on the use of human immunoglobulin to treat primary immunodeficiencies, based on a narrative literature review and their professional experience, the members of the Primary Immunodeficiency Group of the Brazilian Society of Allergy and Immunology prepared an updated document of the 1st Brazilian Consensus, published in 2010. The document presents new knowledge about the indications and efficacy of immunoglobulin therapy in primary immunodeficiencies, relevant production-related aspects, mode of use (routes of administration, pharmacokinetics, doses and intervals), adverse events (major, prevention, treatment and reporting), patient monitoring, presentations available and how to have access to this therapeutic resource in Brazil.
在过去几年中，已发现了新的原发性免疫缺陷和基因缺陷。最近，巴西已有了成分改良的皮下用人免疫球蛋白产品。为了指导医生使用人免疫球蛋白治疗原发性免疫缺陷，巴西变态反应与免疫学学会原发性免疫缺陷小组的成员基于文献综述和专业经验，编写了2010年发布的第一版巴西共识的更新文件。该文件介绍了免疫球蛋白治疗原发性免疫缺陷的适应症和疗效、相关生产方面、使用方式（给药途径、药代动力学、剂量和间隔）、不良事件（主要的、预防、治疗和报告）、患者监测、现有剂型以及在巴西如何获取这种治疗资源的新知识。
